Among Wednesday’s top online stories for investors: The best way to generate 1,000% returns; how to trade the Korea conflict; is Bank of America the next WikiLeaks target?
Continue reading Daily Blogwatch: Is B…
Among Wednesday’s top online stories for investors: The best way to generate 1,000% returns; how to trade the Korea conflict; is Bank of America the next WikiLeaks target?
Continue reading Daily Blogwatch: Is B…
At a liver disease conference in Boston, one highlight is expected to be reports from Achillion about its new hepatitis C treatments, especially ACH-1625. The buzz is growing that the little biotech is attracting the attention …
Swiss pharmaceutical company Novartis announced Tuesday that it had discontinued the development of two drugs — the hepatitis C treatment Zalbin, and antifungal agent Mycograb. The company will take impairment charges of appro…